High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A 'GISCAD' phase III study

Annals of Oncology

Volumn 8, Issue 2, 1997, Pages 169-174

  Labianca, R ^a   Cascinu, S ^a   Frontini, L ^a   Barni, S ^a   Fiorentini, G ^a   Comella, G ^a   Zaniboni, A ^a   Gottardi, O ^a   Arnoldi, E ^a   Oliani, C ^a   Duro, M ^a   Pavanato, G ^a   Martignoni, G ^a   Raina, A ^a   Piazza, E ^a   Dallavalle, G ^a   Valsecchi, R ^a   Pancera, G ^a   Luporini, G ^a  

^a SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

5 fluorouracil; biochemical modulation; colorectal cancer; high versus low dose; L leucovorin

Indexed keywords

FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0013405202     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008200713533     Document Type: Article

References (35)

1. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
2. O'Connell MJ, Maillard J, MacDonald J et al. An intergroup trial of intensive-course 5-FU and low-dose leucovorin as surgical adjuvant therapy for high-risk colon cancer. Proc Am Soc Clin Oncol 1993; 12: 552 (Abstr).
3. Wolmark N, Rockette H, Fisher B et al. The benefit of leucovorin-modulated fluorouracil as post-operative adjuvant therapy for primary colon cancer: Results from the National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993; 11: 1879-87.
4. Francini G, Petrioli R, Lorenzini L et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterol 1994; 106: 899-906.
5. IMPACT Investigators (Labianca R, Marsoni S, Pancera G et al.). Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939-44.
6. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330: 1136-42.
7. Buroker TR, O'Connell MJ, Wieand HS et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994; 12: 14-20.
8. Erlichman C, Fine S, Kerr I et al. A phase II trial of 5-fluorouracil and 1-leucovorin. A multicentre experience. In Rustum YM, Moran R (eds): Novel Approaches to Selective Treatment of Human Solid Tumors: Laboratory and Clinical Correlation. Proceedings of an International Symposium. Buffalo: Roswell Park Cancer Institute Press 1992; 30-2.
9. Rosso R. Mazzei T, Sobrero A et al. Phase II trial of 5-fluorouracil and the natural 1-isomer of folinic acid in the treatment of advanced colorectal carcinoma. Eur J Cancer 1994; 30A: 338-43.
10. Miller AB, Hoogstraten B. Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
11. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-70.
13. Fisher RA, Yates F. Statistical Tables for Biological. Agricultural and Medical Research (6th ed.). New York: Hafner 1964.
14. Pearson ES. Hurtley HO. Biometrika Tables for Statisticians (3rd ed.). Cambridge: Cambridge University Press 1966; Vol 1.
15. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
16. Pazdur R, Lassere Y, Rhodes Vet al. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen for the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994; 12: 2296-300.
17. Bajetta E, Colleoni M, Di Bartolomeo M et al. Doxifluridine and leucovorin: An oral treatment combination in advanced colorectal cancer. J Clin Oncol 1995; 13: 2613-9.
18. Cunningham D, Zalcberg JR, Rath U et al. Tomudex (ZD 1694): Results of a randomized trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995; 31A: 1945-54.
19. Slichenmyer WJ, Rowinsky EK, Donehwer RC et al. The current status of camptothecin analogues as antitumour agents. J Natl Cancer Inst 1993; 85: 271-9.
20. Machover D, Diaz-Rubio E, de Gramont A et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996; 7: 95-8.
21. Leichman CG, Fleming TR, Muggia FM et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 1995; 13: 1303-11.
22. Doroshow JH. Biochemical modulation of fluoropyrimidines: Is there an optimal (6R.S) leucovorin schedule? J Natl Cancer Inst 1996; 88: 393-5.
23. Petrelli N, Douglass HD, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma. A prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419-26.
24. Jaeger E, Klein O, Bernhard H et al. Weekly high-dose folinic acid (FA)/5-fluorouracil (FU) versus low-dose FA/FU in advanced colorectal cancer. Results of a randomized multicenter trial. Proc Am Soc Clin Oncol 1994; 13: 556 (Abstr).
25. Poon MA, O'Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil. Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-17.
26. Poon MA, O'Connell MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967-72.
27. Cao C, Frank C, Rustum Y. Role of fluoropyrimidine schedule and (6R,S) leucovorin dose in a preclinical animal model of colorectal carcinoma. J Natl Cancer Inst 1996; 88: 430-6.
28. Etienne MC, Guillot T, Milano G, Critical factors for optimizing the 5-fluorouracil/folinic acid association in cancer chemotherapy. Ann Oncol 1996; 7: 283-9.
29. Petrelli N, Rustum Y. Fluorouracil and leucovorin: There is a choice. J Clin Oncol 1993; 11: 1434.
30. Brook J. Fluorouracil and low-dose leucovorin versus fluorouracil and high-dose leucovorin. What is the real cost? What is the answer? J Clin Oncol 1995; 13: 1830-1.
31. de Gramont A, Bosset JF, Milan C et al. A prospective randomized trial comparing 5-FU bolus with low-dose folinic acid (FU-FOLId) and 5-FU bolus plus continuous infusion with high-dose folinic acid (LV5-FU2) for advanced colorectal cancer. Proc Am Soc Clin Oncol 1995; 14: 455 (Abstr).
32. Goldberg RM, O'Connell MJ, Wieand HS et al. A prospective randomized trial of intensive course 5-FU combined with a) the 1-isomer of intravenous leucovorin. b) oral (d.1) leucovorin or c) intravenous (d.1) leucovorin for the treatment of advanced colorectal cancer. A North Central Cancer Treatment Group trial. Proc Am Soc Clin Oncol 1996; 15: 471 (Abstr).
33. Machover D, Goldschmidt E, Chollet P et al. Treatment of advanced colorectal and gastric adenocarcinoma with 5-FU and high-dose folinic acid. J Clin Oncol 1986; 4: 685-90.
34. Glimelius B, Hoffman K, Graf W. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994; 73: 556-62.
35. Wadler S, Schwartz EL. Chemotherapy for colorectal carcinoma: Observations regarding recent clinical trials using biochemical modulation. J Clin Oncol 1995; 13: 2676-80.